Rosa & Co. Announces the Appointment of Sharan A. Pagano as Vice President, Scientific Alliances, and the Opening of Rosa’s Boston-area Office

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the appointment of Sharan A. Pagano, Vice President, Scientific Alliances, responsible for worldwide sales and account development, and the opening of Rosa’s new Boston, MA-area office.

"I am pleased to welcome Sharan to the Rosa management team. Her unique blend of business and scientific expertise is an excellent fit for Rosa and our clients. She will expand our current scientific collaborations and enable new clients to tap into the strategic advantages of drug-disease modeling. In addition, opening the Boston-area office will allow us to better serve the many innovative life science firms there.”

Ms. Pagano brings over 25 years of international business and scientific experience, in which she held leadership positions in business development, international sales and marketing, and product and process sciences. She joins Rosa from Entelos Inc., a systems biology company, where she held a senior business development position and was responsible for establishing and maintaining broad, multi-year, R&D partnerships with pharmaceutical and consumer companies. Prior to Entelos, Ms. Pagano was the vice president of business development and alliances at Genstruct (now Selventa), where she developed and managed significant relationships with top-twenty pharmaceutical companies. Previously, Ms. Pagano also held sales and scientific management positions at Incyte Genomics, Proteome Inc., and Genetics Institute (now Pfizer). Ms. Pagano received her Bachelor of Science degree in Biology from Merrimack College and her Master of Science degree in Pharmacognosy from the University of Minnesota.

About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

Rebecca Baillie
Rosa & Co. LLC
751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.